Oxford, UK- 24 April 2009 – PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures’ pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.
Dr Fintan Walton, CEO, PharmaVentures commented, “This research centre is a rare opportunity for a pharmaceutical company or contract research organisation to expand its operations and gain access to one of the world’s foremost research centres.”
For press enquiries, please contact:
Dr Fintan Walton, CEO
PharmaVentures
fintan.walton@pharmaventures.com
+44 (0) 1865 784 187
For enquiries about this opportunity, please contact:
Kevin Bottomley
Senior Principal
PharmaVentures
kevin.bottomley@pharmaventures.com
+44 (0) 1865 784 185
– ends –